Brain-Computer Interface (BCI), as a disruptive human-computer interaction technology that breaks through biological neural boundaries, focuses on building a direct connection channel between the brain and external devices through a two-way communication mechanism of "brain-reading decoding" and "brain-writing encoding," serving as the core carrier for future human-machine integration. The industry has currently developed invasive, semi-...

Neuralink's first product, Telepathy, is expected to enter mass production this year, with over 10,000 people having applied to experience it. Telepathy focuses on severely affected groups with "normal brain function but disrupted motor/communication pathways," such as those with spinal cord injuries or ALS...

Small nucleic acid drugs have obvious advantages and are expected to lead the upgrade of treatment paradigms. Small nucleic acid drugs act on pre-mRNA or mRNA in cells based on the principle of base complementary pairing, achieving the purpose of treating diseases by regulating protein expression. Compared with small molecule and antibody drugs, small nucleic acid drugs...

Driver gene-negative refers to the absence of detectable actionable driver gene mutations in tumor samples, accounting for 31% of newly diagnosed NSCLC patients in both China and the United States. Based on current guidelines from both countries, first-line treatment for driver gene-negative advanced NSCLC patients primarily relies on PD-(L)1 ± chemotherapy…

In January, the "Regulations for the Implementation of the Drug Administration Law of the People's Republic of China" was released. The Ministry of Commerce and nine other departments issued opinions on promoting the high-quality development of the pharmaceutical retail industry. The National Drug Supervision and Administration Conference was held in Beijing in 2026, and the sixth batch of national high-value medical consumables procurement was also opened. In December...

"Implementation Plan for High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)" Encourages Promotion of Ethnic Medicines and Prestigious BrandsOn February 5, 2026, eight departments including the Ministry of Industry and Information Technology jointly issued the "Implementation Plan for High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)," outlining the development of the traditional Chinese medicine industry for the next five years...

The turning point for innovative drug companies to reverse losses has arrived, with a dense catalytic period of clinical data throughout the year. Combined with the smooth progress of overseas clinical pipelines that have been BD-exported, we are optimistic about the investment opportunities in the innovative drug sector. According to statistics from Yibao Magic Cube, the number of new drug License-out transactions in China will reach 158 in 2025, with a total transaction scale...

In January 2026, there were a total of 33 M&A transactions in the global healthcare sector, with the publicly disclosed total transaction value amounting to approximately US$2.717 billion (approximately RMB 19.397 billion). The domestic market saw two M&A events, with no disclosure of the total transaction amount; overseas markets witnessed 31 M&A events…

China's innovative drug sector is upgrading from being a "global participant" to an "innovation hub," driven by the triple resonance of policy, capital, and technology. By 2026, it is expected to be the year of concentrated fruition across multiple tracks. Overseas expansion environment: Regulatory recovery + global demand resonance, true innovation is entering a window of opportunity. After undergoing personnel and procedural adjustments, the FDA...

Since the State Council released the "Opinions on Reforming the Review and Approval System for Drugs and Medical Devices" ("Document 44") in 2015, China's innovative drug industry has undergone a profound strategic transformation and systematic reconstruction, achieving a historic leap from being "dominated by generics" to "innovation-led." Over the past decade, in ...

Deeply Cultivating the Orthopedic Surgical Robot Field, Occupying a Market Leadership Position. The company is a leading enterprise in China's orthopedic surgical robot industry, dedicated to reshaping orthopedic surgical procedures through intelligent technology, integrating upstream and downstream technical resources, and building an intelligent orthopedic surgery platform. In 2020, the company successfully went public with an IPO...

J.P. Morgan Healthcare Conference, which began in 1982, is one of the most influential and largest healthcare investment industry cooperation and exchange conferences in the global healthcare field, covering pharmaceuticals, biotechnology...